PDCD1 and cancer: Despite the promising impact of cancer immunotherapy targeting CTLA4 (e.g. ipilimumab) and PD1/PDL1 (e.g. pembrolizumab), with in-depth research, the side effects and resistance of these drugs have gradually emerged (70, 71).